. 2012 Dec 1;1(9):1584–1593. doi: 10.4161/onci.22660

Table 2. Mouse melanoma TIDC characteristics.

Model	DC marker	Frequency	DC subpopulation	Characteristics
Scid-MV3 xenograft¹⁰⁵	BSA-I binding	~35/5 high power fields	-	-
B16/F10. s.c.⁷³	CD11c⁺, MHCII⁺	-	All CD11b⁺; further negative for EpCAM, PDCA-1, CD4, CD8α	Partially activated; reduced capacity for protein uptake and subsequent MHC II presentation; less sensitive to TLR stim.
B16/F10. s.c.⁷⁵	CD11c⁺, MHCII⁺	-	All CD11b⁺; most F4/80⁺ ~23.5%, GR1⁺; few pDC	GR1+ less mature populations, fails to stimulate MLR, produce more IL-10; protein pulsed Gr1+ DC poorly activate OVA-specific CD4 and CD8 T cells in vivo
B16/F10 sec.c.⁷⁷	CD11c⁺, MHCII⁺			Pre-DC (Lin-CD11c+MHCII-Flt3+) cells are recruited in the tumor, differentiate and activated CD8 T cells in vitro upon peptide pulsing
B16/F10 sec.c.⁹²	CD11c⁺	-	-	TIDC express high levels of SOCS3 and have reduced M2-PK activity.
B16-OVA s.c.⁷⁴	CD11c⁺, MHCII⁺	~30% of TIL	Mostly CD11b⁺, ~5% pDC, hardly CD207⁺	Immature phenotype; fail to activate OVA-specific CD4 and CD8 T cells ex vivo
B16-OVA s.c.⁷⁰	CD11c⁺	~20% of TIL	~33% CD11b⁺MHCII^high, rest CD11b- MHCII^medium	Partially mature; no in vitro activation of OVA-specific CD4 and poor activation of CD8 T cells
B16/F10 sec.c⁷¹^,⁸¹	CD11c⁺, MHCII⁺	0.13 ± 0.07% of total cells	~3% pDC, ~2.25% CD8αDC, > 95% non-pDC non CD8α	Decreased number compared with skin; Immature phenotype, particle uptake in vivo normal; protective upon transfer.
K17–35⁷¹	CD11c⁺, MHCII⁺	4.0 ± 0.22% of total cells	~15% pDC, ~12% CD8αDC	Increased number compared with skin; immature phenotype; particle uptake in vivo normal
Tyr:N-Ras^Q61K+ DMBA/C₃H₆O⁷¹	CD11c⁺, MHCII⁺	0.02 ± 0.004 of total cells	~58% pDC, ~40% non pDC non CD8αDC	Decreased number compared with skin; immature phenotype
MT/ret⁷²	CD11c⁺, MHCII⁺	3–10% of TIL	-	Increasingly immature phenotype upon melanoma progression